Yu L - Search Results

1

Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain.

Mohamed AJ, Yu L, Bäckesjö CM, Vargas L, Faryal R, Aints A, Christensson B, Berglöf A, Vihinen M, Nore BF, Smith CI. Mohamed AJ, et al. Among authors: yu l. Immunol Rev. 2009 Mar;228(1):58-73. doi: 10.1111/j.1600-065X.2008.00741.x. Immunol Rev. 2009. PMID: 19290921 Review.

2

Regulation of Bruton tyrosine kinase by the peptidylprolyl isomerase Pin1.

Yu L, Mohamed AJ, Vargas L, Berglöf A, Finn G, Lu KP, Smith CI. Yu L, et al. J Biol Chem. 2006 Jun 30;281(26):18201-7. doi: 10.1074/jbc.M603090200. Epub 2006 Apr 27. J Biol Chem. 2006. PMID: 16644721 Free article.

3

Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-kappaB.

Yu L, Mohamed AJ, Simonson OE, Vargas L, Blomberg KE, Björkstrand B, Arteaga HJ, Nore BF, Smith CI. Yu L, et al. Blood. 2008 May 1;111(9):4617-26. doi: 10.1182/blood-2007-10-121137. Epub 2008 Feb 21. Blood. 2008. PMID: 18292289 Free article.

4

NF-kappaB regulates the transcription of protein tyrosine kinase Tec.

Yu L, Simonson OE, Mohamed AJ, Smith CI. Yu L, et al. FEBS J. 2009 Nov;276(22):6714-24. doi: 10.1111/j.1742-4658.2009.07385.x. Epub 2009 Oct 16. FEBS J. 2009. PMID: 19843184 Free article.

5

TEC family kinases in health and disease--loss-of-function of BTK and ITK and the gain-of-function fusions ITK-SYK and BTK-SYK.

Hussain A, Yu L, Faryal R, Mohammad DK, Mohamed AJ, Smith CI. Hussain A, et al. Among authors: yu l. FEBS J. 2011 Jun;278(12):2001-10. doi: 10.1111/j.1742-4658.2011.08134.x. Epub 2011 May 18. FEBS J. 2011. PMID: 21518255 Free article. Review.

6

Proteasome inhibitors block HIV-1 replication by affecting both cellular and viral targets.

Yu L, Mohanram V, Simonson OE, Smith CI, Spetz AL, Mohamed AJ. Yu L, et al. Biochem Biophys Res Commun. 2009 Jul 17;385(1):100-5. doi: 10.1016/j.bbrc.2009.04.156. Epub 2009 May 6. Biochem Biophys Res Commun. 2009. PMID: 19426715

7

Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects.

Estupiñán HY, Bouderlique T, He C, Berglöf A, Gupta D, Saher O, Daza Cruz MÁ, Peña-Perez L, Yu L, Zain R, Karlsson MCI, Månsson R, Smith CIE. Estupiñán HY, et al. Among authors: yu l. Blood Adv. 2020 Jun 9;4(11):2439-2450. doi: 10.1182/bloodadvances.2019001319. Blood Adv. 2020. PMID: 32492159 Free PMC article.

8

BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.

Estupiñán HY, Wang Q, Berglöf A, Schaafsma GCP, Shi Y, Zhou L, Mohammad DK, Yu L, Vihinen M, Zain R, Smith CIE. Estupiñán HY, et al. Among authors: yu l. Leukemia. 2021 May;35(5):1317-1329. doi: 10.1038/s41375-021-01123-6. Epub 2021 Feb 1. Leukemia. 2021. PMID: 33526860 Free PMC article.

9

Transcriptional signatures of Itk-deficient CD3+, CD4+ and CD8+ T-cells.

Blomberg KE, Boucheron N, Lindvall JM, Yu L, Raberger J, Berglöf A, Ellmeier W, Smith CE. Blomberg KE, et al. Among authors: yu l. BMC Genomics. 2009 May 18;10:233. doi: 10.1186/1471-2164-10-233. BMC Genomics. 2009. PMID: 19450280 Free PMC article.

10

Tec family kinases.

Yu L, Smith CI. Yu L, et al. FEBS J. 2011 Jun;278(12):1969. doi: 10.1111/j.1742-4658.2011.08135.x. Epub 2011 May 18. FEBS J. 2011. PMID: 21518256 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

26,266 results

Search Page

Filters